Reporting owner · CIK 0001589597
Wilson Troy Edward
SEC Form 4 history across 2 companies, 3 transactions and 3 filings.
DIRPUMA BIOTECHNOLOGY, INC.
Open-market transaction mix67% buys2 buys · 1 sales
Available history · Aug 17, 2026 – Sep 14, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
PBYIPUMA BIOTECHNOLOGY, INC. | Wilson Troy EdwardDIR | S · sale10b5-1 detectedSEC filing ↗ | -$45.5kView disclosure → | |
KURAKura Oncology, Inc. | Wilson Troy EdwardPRES | P · buySEC filing ↗ | $1.23MView disclosure → | |
KURAKura Oncology, Inc. | Wilson Troy EdwardPRES | P · buySEC filing ↗ | $1.11MView disclosure → |
Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
sale at PUMA BIOTECHNOLOGY, INC. on Sep 14, 2026 valued at $45,500.
Review SEC filingMonthly open-market activity
Last 2 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Aug 2026 | 2 | 0 | $2,351,000.00 | $0.00 | $2,351,000.00 |
| Sep 2026 | 0 | 1 | $0.00 | $45,500.00 | -$45,500.00 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$798.8K
Median P/S size$1.1M
Direct1
Indirect2
Sep 14, 2026sale
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
1 observations · Sep 14, 2026 – Sep 14, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 14, 202654,750 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 14, 2026 | 54,750 | Sep 17, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Wilson Troy Edward Insider Activity FAQ
SEC Form 4 context
Who is Wilson Troy Edward?
Wilson Troy Edward is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001589597.
Which companies has Wilson Troy Edward reported transactions for?
PUMA BIOTECHNOLOGY, INC., Kura Oncology, Inc., Avidity Biosciences, Inc.
When was Wilson Troy Edward's latest insider buy?
buy at Kura Oncology, Inc. on Aug 24, 2026 valued at $1,239,000.
When was Wilson Troy Edward's latest insider sale?
sale at PUMA BIOTECHNOLOGY, INC. on Sep 14, 2026 valued at $45,500.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.